Johnson & JohnsonvsLakefront Biotherapeutics

JNJ and LKFT stock compared: price, dividend, valuation and results, from SEC filings.

LKFT

Lakefront Biotherapeutics

$33.31

Value $2.2B

-0.24%
LKFT's page

Johnson & Johnson (JNJ) has a market value of $652B and Lakefront Biotherapeutics (LKFT) $2.2B. Over the last year, with dividends, JNJ moved +36.6% and LKFT +9.2%. The P/E is 40.5 for JNJ and 5.8 for LKFT. Dividend yield: JNJ 1.95%, LKFT none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$652B

    LKFT$2.2B

    JNJ is 297 times LKFT

  • Revenue, 12 months

    JNJ$99.3B

    LKFT$1.3B

    JNJ is 76 times LKFT

  • Net income, 12 months

    JNJ$16.1B

    LKFT$377M

    JNJ is 43 times LKFT

  • Operating margin

    JNJ–

    LKFT26.5%

  • ROIC

    JNJ12.4%

    LKFT7.2%

    5.2 points apart

  • P/E

    JNJ40.5

    LKFT5.8

    JNJ is 6.9 times LKFT

  • Dividend yield

    JNJ2.0%

    LKFT0.0%

    2.0 points apart

  • 5-year return

    JNJ+90.9%

    LKFT-35.3%

    126.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+90.9%

LKFT-35.3%

5010015020020222023202420252026
Returns by period
PeriodJNJWith dividendsLKFTWith dividends
1 year since November 19, 2025+36.6%Price +33.6%+9.2%Price +9.2%
3 years since November 20, 2023+94.9%+24.9% a yearPrice +80.4%-10.9%-3.8% a yearPrice -10.9%
5 years since November 19, 2021+90.9%+13.8% a yearPrice +66.0%-35.3%-8.3% a yearPrice -35.3%
10 years since November 22, 2016+212.6%+12.1% a yearPrice +139.9%-42.5%-5.4% a yearPrice -42.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonLKFTLakefront Biotherapeutics

Valuation

JNJLKFT
Valuation
Price$270.47$33.31
Market value$652B$2.2B
Enterprise value (EV)$679B$2.1B
P/E40.55.8
P/E, 5-year median21.911.5
P/B8.00.6
EV/EBIT38.36.1
Free cash flow yield3.2%–

Results and growth

JNJLKFT
Results and growth
Revenue, 12 months$99.3B$1.3B
Net income, 12 months$16.1B$377M
Free cash flow, 12 months$20.6B-$318M
Earnings per share, 12 months$6.59$5.72
Revenue growth, year on year6.1%303.5%
Revenue growth a year, past+2.7%over 5 years+18.4%over 5 years
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJLKFT
Margins and returns on capital
Gross margin67.6%97.3%
Operating margin–26.5%
Net margin16.2%28.8%
ROIC12.4%7.2%
ROE19.7%9.9%

Balance sheet

JNJLKFT
Balance sheet
Cash$17.2B$103M
Total debt$44.7B$8.1M
Net debt / EBITDA1.1–
Interest cover18.0×–

Dividends and buybacks

JNJLKFT
Dividends and buybacks
Dividend yield2.0%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or LKFT

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Lakefront Biotherapeutics?

By market value, Johnson & Johnson ($652B) is about 296.9 times Lakefront Biotherapeutics ($2.2B), at today's prices.

How did JNJ and LKFT stock do over the last 10 years?

Since November 22, 2016, JNJ's price moved +139.9% and LKFT's -42.5%. With dividends: JNJ +212.6% (+12.1% a year), LKFT -42.5% (-5.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or LKFT?

The dividend yield at today's price is 1.95% for Johnson & Johnson and none for Lakefront Biotherapeutics. Over the last twelve months they paid $5.28 and – per share.

What is the P/E of JNJ and LKFT?

At today's price, the P/E is 40.5 for JNJ and 5.8 for LKFT. The median of the last five years was 21.9 and 11.5, which shows where each stands against its own past.

Which has the higher profit margins, Johnson & Johnson or Lakefront Biotherapeutics?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 28.8% for Lakefront Biotherapeutics, and the operating margin – and 26.5%. Revenue was $99.3B and $1.3B.

Which is the better investment, Johnson & Johnson or Lakefront Biotherapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.